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RSK2 is a p90 ribosomal S6 kinase family (p90RSK) member regulating cell prolifera-
tion and transformation induced by tumor promoters such as epithelial growth factor
(EGF) and 12-O-tetradecanoylphorbol-13-acetate. This family of p90RSK has classified as
a serine/threonine kinase that respond to many growth factors, peptide hormones, neu-
rotransmitters, and environmental stresses such as ultraviolet (UV) light. Our recent study
demonstrates that RSK2 plays a key role in human skin cancer development. Activation
of RSK2 by EGF and UV through extracellular-activated protein kinases signaling pathway
induces cell cycle progression, cell proliferation, and anchorage-independent cell transfor-
mation. Moreover, knockdown of RSK2 by si-RNA or sh-RNA abrogates cell proliferation
and cell transformation of non-malignant human skin keratinocyte, and colony growth of
malignant melanoma (MM) cells in soft agar. Importantly, activated and total RSK2 protein
levels are highly detected in human skin cancer tissues including squamous cell carcinoma,
basal-cell carcinoma, and MM. Kaempferol and eriodictyol are natural substances to inhibit
kinase activity of the RSK2 N-terminal kinase domain, which is a critical kinase domain to
transduce their activation signals to the substrates by phosphorylation. In this review, we
discuss the role of RSK2 in skin cancer, particularly in activation of signaling pathways and
potent natural substances to target RSK2 as chemopreventive and therapeutic agents.
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INTRODUCTION
Skin cancer is the most common of all cancer types in human.
Over two-million new cases of skin cancer are diagnosed annu-
ally in the United States (U.S.) and this accounts for over 40% of
all new cancer cases (1). Skin cancer rate in the U.S. is increasing
because of the ultraviolet (UV)-light influence by the depletion of
ozone layer of atmosphere and aging population.
Skin cancer is categorized by outermost layer of the skin called
epidermis; it is composed of three layers: an upper and the mid-
dle layers are made up of squamous cells, and the bottom layer
is made up of melanocytes and basal cells. Basal-cell carcinoma
(BCC) is the most common form of skin cancer accounting for
more than one million cases which were diagnosed in U.S. dur-
ing the year 2009 (2). Squamous cell carcinoma (SCC) accounts
for 16–20% of skin cancer cases and occurs twice as often in men
than in women. Although basal-cell carcinoma rarely metasta-
sizes, it can cause significant destruction and disfigurement by
invading surrounding tissues, so it is considered to be malignant
(3, 4). According to U.S. statistics report, approximately 3 out of
10 Caucasians may develop BCC in their life period (5). The most
common skin cancer is BCC affecting one in seven individuals
over a life period in Canada (6). In 80% of all cases, BCC is found
on the head and neck (5). Melanoma (from Greek melas mean
“dark”) is a malignant tumor of melanocytes in any part of the
body (3, 4). Melanocytes occur not only in skin, but also in other
parts of the body, including the bowel and the eye, and produce
the dark pigment, melanin, which is responsible for the color of
skin. Although melanoma is less common than other skin cancers,
it is more dangerous if it is not diagnosed early because it causes
about 75% of the majority of deaths related to skin cancer (5, 7).
In worldwide, approximately 160,000 new cases of melanoma are
diagnosed annually.
The main risk factor for non-melanoma skin cancer is sun-
light (1). The UV part of sunlight is subdivided according to
wavelength-UVA (320–400 nm), UVB (280–320 nm), and UVC
(200–280 nm). Generally UV light on the earth surface contains
90–99% of UVA and 1–10% of UVB according to geographi-
cal location, season, and weather condition (8). UVC is usually
absorbed in ozone layer of the earth atmosphere. UVB irradiation
induces DNA damage, which can be replicated to generate muta-
tions in many genes containing tumor suppressor TP53 and Ras
(1). This process generally designated as “initiation”; so UVB can
act as an initiator. UVA generates heat and induces activation of
diverse cellular signaling pathways. Because of UVA’s weak initi-
ating activity, UVA is known to as a potent “promoter.” Based on
these reasons, sunlight is a most abundant complete carcinogen
for the skin cancer initiation and promotion in our environment.
The mitogen activated protein kinase (MAPK) signaling path-
ways plays a central role in diverse cancer development in human.
Growth factors, cytokines, and environmental stresses such as UV
activate receptor tyrosine kinases in cytoplasmic membrane (1, 8).
The activated signals in the cytoplasmic membrane are transmitted
to nucleus through phospho-conveyer systems including MAPK
signaling pathways, which are composed of extracellular-activated
www.frontiersin.org August 2013 | Volume 3 | Article 201 | 1
Arul and Cho RSK2 in human skin cancer
protein kinases (ERKs), p38 kinases, and Jun N-terminal kinases
(JNKs) (8). The signaling induces c-fos gene expression and phos-
phorylation of c-Jun at Ser63 and Ser73 (Ser63/73), resulting to
form a Jun/Fos dimer (AP-1 transcription factor complex) (1, 8).
About over 50% of cellular genes are regulated their gene expres-
sion by AP-1, particularly genes involved in cell proliferation,
transformation, and cancer development (1).
The p90RSK (ribosomal protein S6 kinase: RSK) is a family
of 90 kDa serine/threonine kinases, which are composed of N-
terminal domain (NTD), linker region (LR), C-terminal domain
(CTD), and two kinase domains designated as N-terminal kinase
domain (NTKD) and C-terminal kinase domain (CTKD) (9–11).
ERKs, which can be activated by stimulation of growth factors,
cytokines, and/or environmental stresses through a phosphoryla-
tion cascade system, activate RSKs including RSK1, RSK2, RSK3,
MSK1, and MSK2. RSKs play an important role in activation of
downstream transcription factors involved in cell proliferation,
transformation, and cancer development (12–19). Importantly,
RSK2 is genetically and physiologically linked with human genetic
disease known as Coffin–Lowry Syndrome (CLS), but not in RSK1,
RSK3, MSK1, and MSK2, indicating that RSK2’s physiological
function is not redundant with other RSKs isotypes (20). More-
over, extensive studies on the RSK2 function in cell proliferation,
transformation, and cancer development have demonstrated that
RSK2 is an important kinase involved in human skin cancer devel-
opment (16, 17, 19). In this review, we will discuss the role of RSK2
and a molecular target as a chemopreventive or therapeutic agent
in human skin cancer.
RSK2 STRUCTURE
Since RSKs is discovered in Xenopus laevis oocytes by Erikson
and Maller as a kinase to phosphorylate the 40S ribosomal sub-
unit protein S6 (21–23), RSKs were classified into two subfam-
ilies including RSKs, RSK1, RSK2, and RSK3, and MSKs, MSK1
and MSK2, based on the amino acid homology and functional
identities (9, 22). The RSK subfamilies share about 80% amino
acid homology, and MSKs subfamily shows about 60% of amino
acid similarity in primary structure. In contrast, RSKs and MSKs
share about 40% of amino acid similarity in primary structure
(Table 1), suggesting that RSKs and MSKs might be functionally
and physiologically separated. In addition, amino acid identities
of RSKs between human and mouse indicates that human RSK1,
RSK2, RSK3, MSK1, and MSK2 shows about 95% of amino acids
similarity with the ortholog of each RSKs in mouse (Table 2),
indicating RSK family members are functionally well conserved
proteins between human and mouse. Hence phylogenic studies
suggested by Hein and his colleagues (24) indicate that a group of
the RSK1 and MSK1 is evolutionally distinct kinase group from
the other kinase group including RSK2 and RSK3. Furthermore,
MSK2 is branched from RSK1, RSK2, RSK3, and MSK1 is the
earliest period in the evolution process (Figure 1A). One of the key
characteristics of RSK family in structure is that RSKs contain two
distinct kinase domains in a single polypeptide chain which has not
been identified in cellular serine/threonine kinases of MAP kinases
(Figure 1B). The NTKD belongs to an AGC group (PKA, PKG,
and PKC) of kinase family, and CTKD is classified as a group of
calcium/calmodulin-dependent (CaMK) kinase family. Recently,
Table 1 | Amino acid homology among human RSKs.
RSK1 RSK2 RSK3 MSK1 MSK2
RSK1 100.0 80.3 79.7 41.3 42.1
RSK2 80.3 100.0 83.4 42.5 42.2
RSK3 79.7 83.4 100.0 42.9 41.1
MSK1 41.3 42.5 42.9 100.0 63.5
MSK2 42.1 42.2 41.1 63.5 100.0
The homology of amino acids was compared with each isoform of human
RSKs. The sequences were obtained from human protein reference database,
http:// www.hprd.org.
Table 2 | Amino acid homology among RSK orthologs between human
and mouse.
Mouse/human RSK1 RSK2 RSK3 MSK1 MSK2
RSK1 96.7 80.5 79.7 42.7 40.9
RSK2 80.5 99.9 83.6 44.8 42.8
RSK3 77.8 83.6 95.6 44.3 39.6
MSK1 41.4 42.0 41.6 96.6 64.0
MSK2 41.0 42.5 42.9 66.6 95.7
The homology of amino acids was compared with each isoform of RSK orthologs
between human and mouse. The amino acid sequences of mouse RSKs were
obtained from National Center for Biotechnology Information, http:// www.ncbi.
nlm.nih.gov/ protein.
FIGURE 1 | Phylogenic tree and RSK2 domain structure. (A)The amino
acid sequences of human RSK1, RSK2, RSK3, MSK1, and MSK2 were
downloaded from human protein reference data base, similarity was
obtained by Jotun Hein method, and phylogenic tree was drawn using the
DNASTAR computer program. (B) A domain structure of RSKs. RSKs,
including RSK1, RSK2, RS3, MSK1, and MSK2, contain two kinase domains
designated as N- and C-terminal kinase domain (NTKD and CTKD), N- and
C-terminal domains (NTD and CTD), and a linker domain in a polypeptide.
The NTKD belong to AGC kinase group kinases and the CTKD has been
classified as CaMK group kinases. The CTD consists of an ERK docking site
and the linker domain contains ERK-mediated and RSK2
auto-phosphorylation sites.
our research group has resolved key structural features of RSK2,
NTKD, and CTKD by X-ray crystallography (25, 26). The struc-
tural analysis demonstrates that auto-inhibitory αL-helix of the
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RSK2 in CTKD embeds in the kinase scaffold and forms inactive
kinase conformation (25). In vitro study of the RSK2 signaling
pathway demonstrates that ERK1 and 2, but not p38 kinases,
are direct upstream kinases to phosphorylate in the LR of RSK2
(17). The result strongly suggests that when RSK2 is activated by
upstream signaling molecules such as ERKs, RSK2 leads to dis-
placement of the αL-helix, resulting in the rearrangement and
reorganization of the T-loop into the active confirmation (25). X-
ray crystal structure of RSK2 NTKD suggests that non-canonical
location of βB-sheet in the N-lobe pushes the αC-helix, result-
ing in the activation of kinase activity by the disruption of the
Lys–Glu interaction (26). Interestingly, the βB-sheet observed in
RSK2 NTKD was found in the NTKD of MSK1 (27), but it is not
detected in the NTKD of RSK1 in the X-ray crystal structure (28).
The amino acid homology between NTKDs of human RSK2 and
MSK1 shows only 54.2%. In contrast, amino acid identity between
RSK1 and RSK2 is about 90.4%. These results suggest that the crys-
tal structure of RSK2 NTKD might closely resemble with RSK1
rather than MSK1. Although novel activation mechanisms of the
RSK2, NTKD, and CTKD have been separately provided by X-
ray crystallography, the whole crystal structure of RSK2 including
N- and CTKDs might need to understand more accurately about
activation mechanism of RSK2 induced by tumor promoters.
RSK2 ACTIVATION MECHANISM AND SIGNALING PATHWAY
Elucidating the RSK activation mechanism is quite challenging
because of diversities of RSK nature, consecutive regulation by
phosphorylation, agonist-specific temporal regulation, changing
spatial distribution, existence of several interacting proteins, and
having two unique kinase domains in a polypeptide. By the stim-
ulation of cells with growth factors, cytokines and environmental
stresses such as UV, RSKs are phosphorylated by multiple kinases
at multiple serine and threonine residues. Notably, these sequential
events are initiated by the activation of the ERK/MAPK cascade
(29). For example, the epidermal growth factor receptor (EGFR) is
a cytoplasmic transmembrane receptor of tyrosine kinase family
involved in the regulation of the proliferation, motility, and differ-
entiation in a variety of cell types (30, 31), and is highly expressed
in cancer (32). EGF and 12-O-tetradecanoylphorbol-13-acetate
(TPA) are well-known tumor promoters inducing malignant cell
transformation in ex vivo cell culture and in vivo animal mod-
els (33). Any of these two agents can induce activation of the
transcription factor activator protein-1 (AP-1) (34, 35). When
JB6 Cl41 mouse skin epidermal cells are stimulated with TPA or
EGF, the cells show an induction of anchorage-independent cell
transformation in soft agar by AP-1’s transcriptional activation
in promotion-sensitive (P+) phenotype of JB6 Cl41 cells but it
is not found in promotion-resistant (P−) phenotype of JB6 Cl41
cells (36). Blocking of the TPA- or EGF-mediated AP-1 activation
causes P+ cells to revert to the P− phenotype, indicates that a
unique requirement for AP-1 activation in EGF- or TPA-induced
cell transformation (37).
Although the stimulations of cells by growth factors potenti-
ate the Ras-ERK signaling pathway mediated by through intra-
cellular signaling molecules such as protein kinase C, PI3-K,
cAMP, and/or cytosolic calcium concentration (38) for the long-
term processes such as synaptic plasticity and memory formation
FIGURE 2 | RSK2 substrates and function of signaling axis. Activated
RSK2 by ERK1/2 transfers the phospho-signal to IκBα and caspase-8,
results in the regulation of inflammation and apoptosis. On the other hand,
activated RSK2 localizes into the nucleus and phosphorylates their
substrates such as p53, NFAT3, histone H3, histone 2AX, ATF1, and other
substrates. Taken together, these functional signaling pathways regulate
diverse biological activities including cell proliferation, transformation,
differentiation, survival, and cancer development.
(39), general EGFR activation induces internal kinase domains
by auto-phosphorylation and transduces their activation signals
to Ras/MEKs/ERKs/RSK2 (38), resulting in the regulation of cell
proliferation and differentiation (Figure 2) (38). RSK2 is a mem-
ber of RSK family of serine/threonine kinases that respond to
growth factors such as peptide hormones and neurotransmit-
ters (38). Because RSK2 contains ERKs docking peptide at CTD
(40, 41), RSK2 can be predominantly phosphorylated by ERKs,
but not by p38 kinase (17). ERKs-mediated phosphorylation at
CTKD (Thr577) and LR (Thr365 and Ser369) of RSK2 initiates
the activation of the C-terminal kinase activity. The activated C-
terminal kinase induces auto-phosphorylation at Ser386 in LR,
which provides a docking site for 3-phosphoinositide-dependent
protein kinase-1 (PDK1), resulting in induction of phosphoryla-
tion at Ser227 in NTKD by PDK1 (42). The N-terminal kinase
activity of RSK2 is increased over 100-folds by phosphoryla-
tion compared with the basal level of non-phosphorylated RSK2
N-terminal kinase activity (42). Our research on the molecu-
lar mechanisms of RSK2 N-terminal kinase activity also proves
that the phosphorylation abilities of RSK2 kinase to the sub-
strates including NFAT3 (261–365) is acquired by the phospho-
rylation of RSK2 NTKD through CTKD-mediated N-terminal
kinase activation mechanisms (Figure 3) (43). As complete acti-
vation of RSK2 NTKD to phosphorylate RSK2 substrates requires
the PDK1-mediated phosphorylation of NTKD, external stimu-
lations inducing RSK2 complete activation might activate both
Ras/Raf/MEKs/ERKs and PI3-K/PKB signaling pathways, result-
ing in immediate induction of gene expression and protein syn-
thesis. Taken together, stimulation of growth factors such as
EGF induces docking of activated ERK1/2 at CTD of RSK2,
resulting in activation of CTKD of RSK2 by ERK1/2-mediated
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FIGURE 3 | Illustration of RSK2 activation mechanisms. The activated
extracellular signal-regulated kinase (ERK) binds at the ERK docking
consensus sequences in the C-terminal domain of RSK2 and phosphorylates
at Thr365/Ser369 in the linker domain and at Thr577 in the C-terminal kinase
domain (CTKD), resulting in the activation of CTKD. The activated CTKD then
phosphorylates at Ser386 in the linker domain, providing a docking site for
PDK1. The PDK1 phosphorylates at Ser227 in the N-terminal kinase domain
(NTKD), resulting in the activation of NTKD. The activated NTKD obtains
ability to phosphorylate the downstream target proteins, which include
kinases, transcription factors, and epigenetic factors.
phosphorylation at LR and CTKD. The activated CTKD of RSK2
induces auto-phosphorylation at LR of RSK2, resulting in appear-
ance of the PDK1 docking site. After binding of PDK1 at the
LR of RSK2, PDK1 phosphorylates and activates RSK2 NTKD
to phosphorylate RSK2 substrates such as NFAT3, ATF1, histone
H3 and H2.
RSK2-MEDIATED CELL TRANSFORMATION
The MAPK signaling pathway not only promotes cell prolifera-
tion but also mediates cell survival, and is up-regulated in various
cancer cells (44). When cells are stimulated with a survival growth
factor, brain-derived neurotrophic factor, RSK2 mediates phos-
phorylation of the proapoptotic protein Bcl-2 associated death
promoter (BAD) (Ser112) (45), indicating that RSK2 is involved
in the survival of neurons. Furthermore, RSK2 deficiency sensi-
tizes the apoptosis induced by calcium ionophore compared with
RSK2+/+ MEFs, indicated that RSK2 might play an important
role in cell survival. On the other hand with RSK2-mediated cell
survival, RSK2 plays an important role in cell proliferation and
transformation. We proposed that RSK2, which is an ERK down-
stream serine/threonine protein kinase, might play a key role in
cell transformation. Our research group confirms that RSK2 is
responded with the stimulation of tumor promoters such as EGF
or TPA in HaCaT human skin keratinocytes. For example, when
HaCaT cells were starved for 24 h with 0.1% FBS-DMEM and then
stimulated with EGF or TPA, phosphorylation and activation of
ERK were increased at 5 min, maintained to 60 min, and decreased
at 120 min after EGF or TPA treatment (16). The phosphorylation
and total protein levels of RSKs including RSK2 was first detected
at 5 min, gradually increased to 120 min, and then decreased at
240 min in a time-dependent manner with EGF or TPA treatment
(16). Additionally, the RSK2 protein level was increased in a sim-
ilar manner to ERK and RSKs. These results indicate that RSK2
is a protein kinase responding to tumor promoters and involv-
ing in tumor progression process. Another important signaling
pathway to phosphorylate RSK2 at Tyr529 was identified by acidic
FGF (aFGF) stimulation (46). The aFGF-mediated RSK2 phos-
phorylation at Ser386 is inhibited by the treatment of U0126,
a specific MEK inhibitor, but not Wortmannin and LY294002,
PI3-K inhibitors, indicating that aFGF-mediated RSK2 activation
requires ERK2-induced C-terminal kinase activation. Importantly,
direct phosphorylation of RSK2 at Tyr529 by FGFR3, a receptor
tyrosine kinase, facilitates the binding of inactive ERK to ERK
docking site in C-terminus of RSK2. This novel signaling path-
way plays an important role in myeloma cell transformation (46).
These results suggest that signaling pathways to activate RSK2 is
not only simple through ERK, but also cooperative with receptor
tyrosine kinase to induce full activation of RSK2 activity.
Another signaling pathway to enhance the skin carcinogenesis
is UV-induced signaling pathway. As described earlier, UV irradia-
tion is the most common environmental carcinogen and is highly
associated with skin carcinogenesis (1). Although it is still con-
troversial that growth factor induces mainly Ras-ERK signaling
pathway rather than p38 kinase and JNKs (18), UV irradiation
induces MAPK signaling pathways including ERKs, p38 kinase,
and JNKs. The MAPK and PI3-K signaling pathways are specific
signaling cascades in UVB-induced skin carcinogenesis (47,48). By
short time exposure of UV in cultured keratinocytes or skin, EGFR
activation is increased, resulting in the activation of the ERKs sig-
naling pathway (49, 50). UVB treatment significantly enhances
ERKs (19) and p38 kinase signaling (8) and inhibition of ERKs
and p38 kinase abrogated UVB-induced c-fos gene transcription
and protein expression as well as AP-1 transactivation activity in
human keratinocytes (8). Our recent research confirmed that UVB
induced RSK2 phosphorylation at Thr577 in the CTKD by ERKs,
resulting in the activation of phosphorylation of the NTKD at
Ser227 (19). Activated RSK2 is localized into the nucleus (19).
In the nucleus, RSK2 seems to induce the substrate phosphoryla-
tions including many transcription factors such as c-Fos as well
as gene transcriptions by enhancing of c-fos gene expression (19),
resulting in the increase of AP-1 complex formation and gene
expression of downstream target genes. However, the molecular
mechanisms of the RSK2 nuclear localization are yet to be studied
clearly. One possible mechanism of the RSK2 nuclear localization
is mediated by p53 protein, a well-known tumor suppressor. Inter-
estingly, p53 protein is identified as a binding partner of the RSK2
(13). RSK2-mediated p53 phosphorylation is confirmed by the
in vitro kinase assay and Western blot analysis using leukemia cells
obtained from patients, who have normal RSK2 genetic allele and
RSK2 deficient CLS patients (13). Importantly the notable point is
UVB stimulation induces p53 phosphorylation at Ser15 (13) and
RSK2 phosphorylation at Thr577 (19). RSK2-mediated p53 phos-
phorylation in cytoplasm induces nuclear p53 accumulation and
increases RSK2 and histone H3 interaction (13). Interestingly p53
deficiency suppresses UV or EGF-induced histone H3 phospho-
rylation at Ser10, which is a RSK2-mediated phosphorylation site
(16) involving cell proliferation and transformation (14).
The critical and physiological linkage between RSK2 and
human skin cancer are made recently by the evidences that RSK2
is expressed in normal human skin tissues in epidermal and basal-
cell layer (19). By the tissue array with human skin normal and skin
cancer tissues, RSK2 protein levels were highly detected in cancer
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tissues compared with normal skin tissues (17, 19). Activated RSK2
by phosphorylation at Thr577 was significantly increased in skin
cancer tissues compared with normal skin tissues (17, 19), indi-
cating that RSK2 protein level and activation are closely related
with human skin cancer development. More direct evidence was
provided by the tissue array using the matched skin cancer tissues
with the normal skin tissues, which was biopsied from adjacent
skin cancer tissues in the same patient. Consequently, the evi-
dences proves that the total and activated RSK2 phosphorylated
at Thr577 is highly detected in cancer tissues compared with the
matched normal skin tissues (17, 19). By extensive analysis with
different skin cancer types in human skin cancer tissue array, SCC,
BCC, and malignant melanoma (MM) contain higher activated-
RSK2 protein levels compared with normal skin tissues (17, 19).
Additionally, the RSK2 protein levels in various cancer cell lines
such as H460, MCF-7, HCT-116, HCT-29, PC-2, Du-145, SoaS-2,
A431, SK-MEL-5, SK-MEL-28, and RPMI 1640 are higher than
compared with non-malignant human and mouse cells includ-
ing HaCaT, JB6 Cl41, and NIH3T3 cells (17). The RSK2-induced
cell proliferation potential has been proved A431 human skin epi-
dermoid carcinoma cell, SK-ML-5, and SK-MEL-28 MM cells are
inhibited by the treatment of kaempferol, a known RSK2 specific
natural compound antagonized RSK2 NTKD activity, in the dose
dependent manner (17). These results indicate that RSK2 activity
is physiologically linked with skin cancer development in human.
The role of RSK2 in cell proliferation was further confirmed by
the knockdown of RSK2 in human skin normal and cancer cells.
RSK2 protein levels were varied according to cells context. For
example, N/TERT-1, immortalized normal cells by over expression
of telomerase, HaCaT, a premalignant human skin keratinocyte,
SCC-13, a SCC cell, and SK-MEL-28, a MM cell, show endoge-
nous different RSK2 protein levels likely as SK-MEL-28> SCC-
13>HaCaT>N/TERT-1 (19). Effectively, RSK2 knockdown by
short hairpin (sh)-RNA RSK2 (sh-RSK2) shows inhibitory effect in
the pattern of the cell proliferation depended on the RSK2 protein
levels. The N/TERT-1, which showed trace amount of RSK2 pro-
tein level, did not affect the cell proliferation by RSK2 knockdown
(19). However, SK-MEL-28 MM cell contained the highest protein
level of RSK2 shows the most significant inhibitory effect of the cell
proliferation by the RSK2 knockdown. The inhibitory effect of the
cell proliferation in these cells is oppositely affected with RSK2 pro-
tein levels as SK-MEL-28> SCC-13>HaCaT>N/TERT-1 (19).
Moreover, RSK knockdown inhibits anchorage-independent cell
transformation induced by tumor promoters such as EGF in
HaCaT cells and anchorage-independent tumor growth of the
SK-MEL-28 MM cell in soft agar (19). Thus, RSK2-mediated cell
proliferation is a main progression effect of cell transformation in
carcinogenesis.
RSK2 is likely to participate in stress tolerance that can enhance
the cell survival. Therefore, RSK2 is believed to stimulate cell sur-
vival (51). The understanding was made by Hemming and Klein
regarding that RSKs might involve the GSK3 inhibitory phos-
phorylation (52, 53). GSK3 activation by dephosphorylation at
serine 21 and 9 induces the cell proliferation and the cell cycle
progression because the cell cycle regulating proteins including
cyclin D1,C/EBP,HSF-1,NFATc,cyclic adenosine monophosphate
response element-binding protein (CREB),Myc, and Jun are under
the control of GSK3 (54). UVB irradiation induces the G1/G0
cell cycle phase accumulation in RSK2−/− MEFs compared with
RSK2+/+ MEFs (19). Moreover, UV-induced RSK2 phosphory-
lates proapoptotic BAD at serine 112, resulting in BAD activity
become null and cell survival increases (55). Importantly, the RSK2
up-regulates the transcription of antiapoptotic Bcl-2 through the
phosphorylation and activation of CREB (45). RSK2-mediated
cell survival signaling pathway is provided by our research group
that caspase-8, a critical enzyme inducing cell apoptosis, is a novel
substrate of RSK2, and the phosphorylation of caspase-8 at thre-
onine 263 by RSK2 induces caspase-8 degradation through the
ubiquitination-mediated proteasomal degradation pathway (56).
The net result of caspase-8 destabilization inhibits cell apopto-
sis, and increases cell survival and cancer development (56). These
results are well consistent with our previous report that RSK2 defi-
ciency suppresses cell proliferation through G1/G0 cell cycle arrest
(16). However, mechanisms of the RSK2/GSK3 signaling pathway
have not been clearly understood. Taken together, activation of
RSK2 through the ERKs signaling pathway induces cell prolifera-
tion mediated by the activation transcription factors involving cell
proliferation and transformation, and the suppression of the cell
death signaling by BAD inactivation and caspase-8 destabilization
(Figure 4).
FIGURE 4 | RSK2-mediated signaling pathways regulate cancer
development. Extracellular stimuli including cytokines, growth factors, and
environmental stresses induces the RSK2 phosphorylation through
receptor tyrosine kinase (RTK), Ras, Raf, MEK, and ERK, resulting in
activation of RSK2. The activated RSK2 phosphorylates the downstream
target proteins including transcription factors such as ATF1 and p53,
epigenetic factors such as histone H3 and histone 2AX, and signaling
molecules such as caspase-8 and IκBα, resulting in the cell proliferation and
transformation, and cancer development.
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RSK2 SUBSTRATES AND CANCER DEVELOPMENT
The CREB is a critical regulator of immediate early gene tran-
scription. Growth factors stimulate CREB phosphorylation at
serine 133 mediated by the Ras-MAPK signaling pathway. RSK2
as a direct upstream kinase of CREB2 at serine 133 was identi-
fied in vitro and in vivo in a decade ago by Greenberg and his
colleagues (57). The activation of CREB2 induces target gene
expressions involved in oncogenesis including osteocalcin (58),
type I collagen, TRB3, E-selectin, asparagines synthetase, and
RANKL (59). ATF1 is classified as an ATF/CREB family mem-
ber. Recently, our research group found that RSK2 interacted with
ATF1 in vitro and ex vivo, and phosphorylated ATF1 at serine 63
(18). RSK2-mediated ATF1 phosphorylation at serine 63 enhances
transactivation and transcriptional activities induced by EGF, and
the point mutation of ATF1 at serine 63 to alanine 63 abolished
RSK2-mediated activation effects of ATF1, resulting in inhibition
of cell transformation in both Ras-induced foci formation and
anchorage-independent cell transformation activities (18). There-
fore, RSK2/ATF1 signaling axis plays an important role in cell
transformation, especially when cells are stimulated with growth
factors such as EGF.
AP-1 is a complex of Jun and Fos and it plays a key role in
gene expression of target genes. The phosphorylations of c-Jun,
a proto-oncogene, at serine 63 and 73 play a key role in AP-1/c-
Jun transcriptional activity. Classically, the c-Jun phosphorylation
at serine 63 and 73 believes through the ERKs signaling pathway
because MEK inhibitors suppress the phosphorylation of c-Jun
at serine 63 and 73 when cells are stimulated by growth fac-
tors such as EGF. However, after JNKs are identified as a kinase
of c-Jun at serine 63 and 73, AP-1/c-Jun activation is exten-
sively studied on the JNK signaling pathway. However, growth
factor-mediated JNKs activation are still controversial because the
phosphorylation of JNKs by growth factors such as EGF is min-
imally detected in ex vivo system, not likely stimulated by UV
irradiation. Recently, CDK3 is identified as a c-Jun kinase at ser-
ine 63 and 73 (43). Interestingly, although murine cells widely
used in ex vivo experiments do not contained endogenous CDK3,
these murine cells still increases c-Jun phosphorylation at serine
63 and 73 by growth factor stimulation. Based on these obser-
vations, there are possibilities that some kinases might exist to
phosphorylate c-Jun at serine 63 and 73 by growth factor stim-
ulation. On the other hand, RSK2 phosphorylates C-terminus of
c-Fos at serine 362, which is a critical transcription factor to reg-
ulate gene expression by formation of AP-1 complex with c-Jun,
resulting in the increase of protein stability and induces osteosar-
coma development (15). Therefore, RSK2 also is an important
kinase to regulate AP-1 activity. However, it is not clear how c-Jun
phosphorylation at serine 63 and 73 is increased by growth factor
stimulation.
In carcinogenesis process, normal cells attain three impor-
tant characteristics including immortalization, clonal propaga-
tion, and cellular morphology change. Especially, cellular mor-
phology change and cell proliferation are closely related with
cytoskeletal gene expression and posttranslational modification,
resulting in rearrangement of cytoskeletons including lamins, ker-
atins, neurofilaments, vimentin, desmin, and others. For example,
keratin 18 can be phosphorylated at serine 52 by CAM kinase,
protein kinase C and RSK2 (60). They further found that mutant
serine 52 of keratin 18 induced cell cycle arrest at the G2/M
stage and was correlated with histone H3 phosphorylation (60).
Importantly, RSK2-mediated histone H3 serine 10 phosphoryla-
tion is confirmed by using RSK2 deficient CLS patient cells. RSK2
deficient human CLS cells are abolished the histone H3 phospho-
rylation at serine 10 by EGF stimulation, and re-introduction of
the wild-type RSK2 to RSK2 deficient CLS patient cells restores
EGF-induced histone H3 phosphorylation at serine 10 (61). Simi-
lar result is obtained by Cho and his colleagues that RSK2−/−MEFs
mimics histone H3 phosphorylation at serine 10 induced by EGF
stimulation (16), and p53 tumor suppressor protein is involved
as an intermediary protein in RSK2-mediated histone H3 phos-
phorylation at serine 10 when the cells are stimulated with EGF
or UV (13). Although a few research groups confirmed that his-
tone H3 phosphorylation is mainly through in MSK1, but not in
RSK2, histone H3 phosphorylation at serine 10 is indispensable for
the cell proliferation and transformation by stimulation of tumor
promoters such as EGF (14).
Interestingly, serine 10 phosphorylation of histone H3 begins
at prophase, reaches the highest level in metaphase and decreases
gradually through the cell cycle to telophase (62), indicating that
the histone H3 phosphorylation at serine 10 might related to
chromosomal condensation process. Recently, our research group
observed that histone 2B (H2B), a histone molecule containing
functional redundancy with histone H3, is a new substrate of
RSK2 to be phosphorylated at serine 32 (63). Although ectopic
expression of the point mutant H2BS32A suppresses marginally
in the cell proliferation and transformation, the phosphorylation
of H2B at serine 32 was dramatically suppressed in RSK2 deficient
MEFs (63). The evidence for the linkage of RSK2 and chromosome
condensation is provided by which RSK2 protein is observed in
G2/M phase of the developing Xenopus oocytes (64). These results
suggest that chromatin condensation in G2/M in cell cycle phase
might be regulated by RSK2 through the phosphorylation of his-
tone 2B and histone H3. However, the molecular mechanisms in
RSK2-mediated chromosome condensation have not been clearly
elucidated yet.
Generally, phosphorylation of proteins is a common regula-
tory mechanism of protein’s activity. Nuclear factor of κ light
polypeptide gene enhancer in B-cell inhibitor α (IκBα) is a key
protein to regulate the activity of NF-κB, which is a key tran-
scription factor involved in the gene expression regulation in
inflammation and cancer development. The IκBα forms and
inhibits NF-κB by masking the NF-κB’s nuclear localization sig-
nals (NLS), results in sequestered them in an inactive state in
the cytoplasm (65). Furthermore, IKKα/β-mediated IκBα phos-
phorylation at serine 32 and 36 creates a binding sites for
the βTrcP ubiquitin ligase complex, resulting in ubiquitination-
mediated proteasomal degradation (66). By IκBα degradation,
the NF-κB translocates to the nucleus and induces gene expres-
sion of many downstream target genes, including a number of
antiapoptotic genes (67–69). Recently, a novel kinase against
IκBα has been identified by our research group that RSK2-
mediated phosphorylation of IκBα affects their protein activi-
ties by through regulation of protein stabilities (70). Similarly
with IKKα/β, RSK2 phosphorylates IκBα at serine 32 in vitro
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and ex vivo. RSK2-mediated IκBα phosphorylation promotes the
ubiquitination of IκBα, resulting in induction of p65 and p50
nuclear localization, NF-κB DNA binding, and transcriptional
activity (70). More importantly, RSK2 activity inhibition with
kaempferol significantly induced the apoptotic cell death when
the cells were co-treated with TNF-α compared with TNF-α alone
(70). These results suggest that RSK2 might play an important
role in cell survival. Furthermore, caspase-8, a principal enzyme
inducing apoptosis, is a novel binding partner of RSK2 and is
phosphorylated at threonine 263 by RSK2 (56). Interestingly,
a tumor promoter such as EGF induces caspase-8 ubiquitina-
tion and reduces half-life of caspase-8. In contrast, knockdown
of RSK2 with si-RNA abrogates EGF-induced caspase-8 ubiqui-
tination and degradation (56). These results imply that activa-
tion of RSK2 induces the activities of downstream transcription
factors and inhibits apoptosis-related enzymes, which play an
important role in cell proliferation and cancer development in
human.
On the other hand, RSK2 substrates also include a tran-
scription factor involved in cell differentiation, NFAT3, and
apoptosis-related protein such as LKB and histone 2AX. LKB is
a kinase as known as a tumor suppressor (71–73). Ectopic overex-
pression of LKB1 suppresses the cell growth by inducing G1 cell
cycle accumulation (71). The phosphorylation of full-length LKB1
at serine 431 does not affect its kinase activity by p90RSK, MSK1,
S6K1, and PKA. However, they found that G361 cells express-
ing the LKB1S431A mutant induce anchorage-independent colony
growth compared with G361 cell expressing wild-type LKB1 (74).
The RSK2-mediated p53 phosphorylation at serine 15 also shows
noncanonical results such as inducing histone H3 phosphorylation
at serine 10 and enhancing cell proliferation and transformation
(13, 14). Furthermore, RSK2 also phosphorylated histone 2AX
at serine 139, which is a key marker amino acid for the double-
strand break (75). Astonishingly, noncanonical phosphorylation
of H2AX at serine 16 and 139 by RSK2 enhances H2AX pro-
tein stability by inhibition of H2AX ubiquitination, resulting in
inhibition of cell transformation. These results showed that RSK2
also regulates the cell death.
The binding of ligands to an appropriate receptor induces con-
formational change of estrogen receptor α (ERα), which enhances
the transcriptional activation function of HBD. They further con-
firmed that a constitutively active mutant of RSK2 induces the
phosphorylation of ERα at serine 167, resulting in enhances phys-
ical association of ERα with HBD. Importantly, anti-estrogen
4-hydroxytamoxifen blocks RSK2-mediated ERα phosphorylation
by the masking of RSK2 docking site (76). These results suggest
that RSK2 can regulate the cell fate depending on the cell context
not only the cell proliferation and transformation, but also the
cell death as summarized in Table 3. Taken together, these results
suggest that RSK2 plays an important role for the determination
of cell fates in both cell survival and cell death.
RSK2 ANTAGONISTS AND INHIBITORS
The ERKs signaling pathway plays a pivotal role in cell prolif-
eration and transformation in carcinogenesis processes. Many
of the human solid cancers including skin, lung, leukemia, and
pancreatic cancer are genetically correlated with constitutive active
Table 3 | RSK2 substrates and cellular function in cell proliferation and
transformation.
Substrate Phosphorylation site Function in cancer
CREB S133 Induction of transactivation activity
ERa S167 Induction of transcriptional activity
Keratin 18 S53 G2/M cell cycle arrest by
cytoskeleton rearrangement
Histone H3 S10 Induction of cell proliferation
NFAT3 S281/S285/S289/S334 Skeletal muscle cell differentiation
LKB1 S431 Inhibition of cell growth
IkBa S32 Ubiquitination-mediated IkBa
degradation
ATF1 S63 Induction of transactivation activity
Caspase-8 T263 Ubiquitination-mediated degradation
H2B S32 Induction of cell proliferation and
transformation
H2AX S139/S16 Induction of protein stability and
inhibition of cell transformation
Ras mutation (RasG12V) (44). Thus, studies on the identification
and development of novel small molecules, which can inhibit Ras-
Raf-MEK-ERK signaling pathway, have rapidly expanded. Our
research group has extensively studied the function of RSK2 in
cell proliferation and transformation and found that RSK2 defi-
ciency suppresses cell proliferation and anchorage-independent
cell transformation compared with RSK2 wild-type MEFs (16).
Further, knockdown of RSK2 with sh-RNA-RSK2 inhibits cell
proliferation, EGF-induced anchorage-independent cell transfor-
mation, and colony growth of malignant human skin cancer cell
in soft agar (19), indicates that RSK2 is a fascinated target to find
small molecule to inhibit RSK2 activity. SL0101, Kaempferol-3-O-
(3′′,4′′-di-O-acetyl-α-l-rhamnopyranoside), is a naturally occur-
ring compound extracted from Froteronica reflecta and inhibits
RSKs’ activities (77, 78). Computational docking model suggests
that SL0101 binds to the ATP-binding pocket of the NTKD of RSK2
(79). In many literatures in nutrition and drug metabolism, we
keenly found that glucuronized chemical compounds are cleaved
in the intestinal flora before absorption and secretes to outside of
body through urine and feces by drug metabolizing enzymes in
the liver (80, 81). Moreover, sugar conjugated natural compounds
are cleaved the sugar moiety in intestinal flora before absorption
by intestinal microorganism (82). Interestingly, inhibitory effect
of SL0101 in the cell proliferation about 50% was required greater
amount with about 20–30µM compared with 87 nM of IC50 of
RSK activity in vitro (77–79). Therefore, our research group con-
sidered that kaempferol might an active compound in human. The
hypothesis was proved that kaempferol inhibited RSK2 activity in
dose dependent manner by in vitro kinase assay (16). Significantly,
although SL0101 is showed inhibitory effects on the RSK fam-
ily including RSK1, RSK2, and RSK3 (77, 78), kaempferol shows
RSK2 specific inhibitory effect, but not RSK1 and RSK3, with
CREB by in vitro kinase assay (16). The computational docking
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analysis of SL0101 and kaempferol suggests the differences bind-
ing modules affecting different IC50 level. For example, hydrogen
bonds between the 5, 7-dihydroxyl moiety of SL0101 and the back
bone of residues Asp148 and Leu150 in the hinge region, and
extra hydrogen bonds, which occur between the ketone oxygen
atom and rhamnose ring oxygen atom of SL0101. Further, they
described the Thr210 hydroxyl group, between 4′-hydroxyl and
rhamnose hydroxyl groups of SL0101, and the Glu197 side chain
carboxylate (79), might give the stronger binding affinity between
SL0101 and RSKs compared with kaempferol and RSK2 binding
affinity. Our study shows to form the hydrogen bonds with Val82,
Asp148, and Leu150 in the hinge region of the NTKD RSK2 (17).
The absent of rhamnose ring in kaempferol might affect the IC50
of kaempferol about 7µM in vitro compared with that of 87 nM
of SL0101. However, it should give the RSK2 selectivity. Although
the crystal structure of the complex of the NTKD of the RSK2
isoform with SL0101 at 1.5 Å resolution has been recently revealed
(83), the crystal structure of RSK2 and kaempferol has not been
reported.
BI-D1870 is a specific cell-permanent inhibitor of all RSK iso-
forms and it binds at the NTKD ATP-binding site. BI-D1870
inhibits the TPA-induced phosphorylation of well-known RSK
substrates such as GSK3α/β and LKB1 at 10µM concentration
in response to agonists that induces the activation of RSKs (84).
BI-D1870 binds at the ATP-binding pocket of the RSK2 NTKD.
The compound shows the inhibition of RSK1 and RSK2 kinase
activities with 10 and 20 nM concentration of IC50, respectively
(84). However structure-based molecular inhibitory mechanisms
have not been reported yet. The pyrrolopyrimidine fmk is a
fluoromethylketone molecule and specifically antagonizes RSK2
activity by targeting RSK2 CTKD with 15 nM of IC50 and 200 nM
of the half maximal effective concentration (EC50) (85). RSK
specificity of fmk is calculated using a bioinformatics analysis of
human protein kinases and found that fmk is stereoelectronically
fit to the CTKD ATP-binding site. The compound induces cova-
lent addition of chloromethylketone to thiol group of Cys436,
which is located in the ATP pocket of RSK2 CTKD, resulting in
the irreversible inhibition of RSK2 C-terminal kinase activities
(85). The treatment of fmk inhibits partially the phosphoryla-
tion of RSK2 at Ser386 in human t (4; 14)-positive, FGFR3-
expressing myeloma cell lines KMS11 and OPM (46), indicating
that fmk cannot completely inhibit the RSK2 C-terminal kinase
activity. Thus, fmk is a different type of RSK2 inhibitor from BI-
D1870 and NTKD targeting compounds including SL0101 and
kaempferol.
Staurosporine is a RSK1 specific inhibitor that binds to the ATP-
binding pocket with the tetrahydropyran ring in a boat conforma-
tion. The crystal structure of staurosporine in complex with RSK1
NTKD indicates that the lactam moiety of staurosporine forms
hydrogen bond to the backbone atoms of Asp142 and Leu144 of
the hinge region which is similar to the RSK2-Ro31-8220 com-
plex model. These two hydrogen bonds are complemented by an
additional hydrogen bond between the N -methyl amino group of
staurosporine and the backbone of carboxyl of Glu91 (28). The
orientation of staurosporine in the ATP-binding site of RSK is
similar to pose in the ATP-binding site of other important kinases
such as CDK (86). By computational docking of RSK2 NTKD
structure with natural compound library, our research group
found that eriodictyol, a natural compound extracted from Yerba
Santa (Eriodictyon californicum), has a similar chemical structure
with kaempferol (18). Furthermore, eriodictyol docks well into
the ATP-binding active site of RSK2 NTKD with−8.816 kcal/mol
of binding affinity (18). Eriodictyol interacts with the backbone
of Asp148 and Leu150 in the hinge region and with the Asp211
of the DFG motif in the lack cleft of the active site (18). By com-
parison with kaempferol docking of the RSK2 NTKD, we found
that the aromatic substituent group of eriodictyol was rotated
out of plane, resulting in a little weaker affinity compared with
kaempferol, which was −9.216 kcal/mol of binding affinity (18).
Eriodictyol suppresses RSK2-mediated ATF1 phosphorylation at
serine 63, which is a novel RSK2 substrate, resulting in inhibition of
cell proliferation and anchorage-independent cell transformation
about 15–20µM of IC50 value (18). Moreover, eriodictyol inhibits
constitutive active Ras-induced foci formation (18). Thus, finding
of natural compounds inhibiting RSK2 activity might be utilized
as a chemopreventive agent.
FUTURE DIRECTION
Previous publications demonstrated that RSK2 is an important
kinase to regulate cell proliferation and transformation. Ectopic
overexpression and knockdown of the RSK2 provides concrete
evidences for the role of RSK2 in human skin cancer develop-
ment. Moreover, our recent X-ray crystallography results of RSK2
CTKD and NTKD might support a critical analysis system to
understand the molecular activation mechanisms of the RSK2 and
the identification of the small molecules inhibiting RSK2 activity.
Importantly, because RSK2 is a signaling molecule by protein–
protein interactions and phosphate group transfer to its substrates,
a remaining important issue is selectivity of inhibitors. Because
many of kinases have a very similar active pocket space, which
can be occupied by ATP, developing small molecules targeting
ATP-binding pocket possess unwanted inhibitory effect on the
other kinases, resulting in serious adverse effects. Our research
group have identified many RSK2 binding partners, including
transcription factors, kinases, and cell fate regulators such as cell
survival and apoptosis, by mammalian two-hybrid system assay.
We believe that protein–protein interaction is more specific com-
pared with small molecule binding to proteins in physiological
system. Thus, the direction to identify the RSK2 selective inhibitors
might target on both the active pocket and interface between
RSK2 and substrates of protein–protein interaction. With RSK2
small molecule inhibitor, the early diagnosis of the particular
cancers can also be considered with total- and activated-RSK2
protein levels. For example, our previous results demonstrated
that RSK2 total- and activated-protein levels were highly detected
in cancer tissues compared with normal tissues. This evidence
also supported with results obtained from various human cancer
cell lines compared with normal or premalignant cell lines. More-
over, total- and phosphorylated levels of RSK2 was higher than
that of normal tissues biopsied from adjacent tissues of cancer
tissues in the same patient. Taken together, these results indicate
that more intriguing studies on the RSK2 are necessary to develop
as a biomarker for particular human cancers such as human skin
cancer.
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